Form Bio Launches In Silico Assays for Gene Therapy Vector Design

Form Bio introduced a new technological development, In Silico Assays, offering gene therapy developers a computational tool to screen vector designs efficiently. This tool aims to accelerate the vector discovery and development process, reducing the typical six to eight-week cycle required for creating and testing new vector designs.

The In Silico Assays provide reports with data comparable to traditional lab-based screenings, such as AUC and mass photometry assays, enabling researchers to assess vector genomes, process impurities, and immunotoxicity factors effectively. As stated by Form Bio's co-CEO Andrew Busey, this capability allows for rapid screening of vast vector libraries, helping to eliminate less promising designs early in the development process.

Located online at forambio.com/isa, the In Silico Assays are designed to help gene therapy companies, Contract Development and Manufacturing Organizations (CDMOs), and Contract Research Organizations (CROs) minimize R&D timelines and costs. By focusing in vitro screenings on the most promising candidates pre-screened in silico, these organizations can potentially enhance the efficacy and cost-efficiency of their development cycles.